|
|
Article: Critical Therapeutics and Dey, L.P. Launch Perforomist(TM) (Formoterol Fumarate) Inhalation Solution.
- Article from:
- Business Wire
- Article date:
- October 8, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LEXINGTON, Mass. -- Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced that the Company has commercially launched Perforomist[TM] (formoterol fumarate) Inhalation Solution (Perforomist) with its marketing partner, Dey, L.P. (DEY), a subsidiary of Mylan Inc. (NYSE: MYL). Perforomist[TM] Inhalation Solution is indicated for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).
Critical Therapeutics and DEY entered into an agreement in June 2007 for the co-promotion of Perforomist. Under the agreement, Critical Therapeutics has agreed to provide a ...